PCRX News and Press, Pacira BioSciences Inc. From 11/10/23

2023-11-10 09:06:08 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioScienc...

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will...

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14 th at 11:00AM...

2023-11-02 15:00:05 ET Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Conference Call November 02, 2023 08:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financ...

2023-11-02 08:04:22 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed Pacira BioSciences: Economic Returns Languish Required Growth Rates ...

-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWS...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Pacira BioSciences Inc. (PCRX) is expected to report $0.65 for Q3 2023

2023-11-02 06:15:00 ET Summary Pacira BioSciences is facing challenges that have impacted their growth trajectory, resulting in the stock hitting 52-week lows. The company offers innovative solutions for non-opioid pain management and regenerative health. The upcoming Q3 earni...

2023-11-01 12:55:04 ET More on Pacira BioSciences Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed Pacira BioSciences: Economic Returns Languish Required Growth Rates Pacira BioSciences CEO David Stack to step down TD Cowen...